Feed PALI
PA

Palisade Bio, Inc.

PALI · NASDAQ

$1.59 -5.36% (-$0.09)
1M -24.29%
Market Cap $348.9M
P/E Ratio -
Div. Yield -
ROE 33.47%

Bulios Fair Price

$1.29

18.9% downside

Current Price

$1.59

Undervalued Fair Value Overvalued

According to Bulios Fair Price, PALI is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
35 /100
Fair
P/B 2.87x
P/S 697.79x
EV/EBITDA N/A
Growth
100 /100
Growing
Book val. growth 118.05%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Net margin 6,388.20%
Op. margin 7,069.80%
FCF margin 3,638.00%
Quality
0 /100
Poor
ROE 33.47%
ROA 25.09%
Asset turnover 0.00x
Debt
69 /100
Low
Current ratio 24.26x
Int. coverage -5,536.67x
Debt/Equity 0.00x
Stability
11 /100
Unstable
EPS volatility 84.41%
Profitable years 0
Beta 1.55x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about PALI
Online

About the company

Palisade Bio, Inc. (PALI) is a biotechnology company focused on the development of novel drugs and therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders. The company is developing drugs and therapies that have the potential to alleviate health issues and improve the quality of life for patients suffering from these conditions. Palisade Bio emphasizes innovation and utilizes modern technologies and scientific knowledge to discover new treatment options. Their goal is to bring new drugs and therapies to the market that can make a real difference and enhance patient care. Palisade Bio is actively involved in research and clinical studies to confirm the effectiveness and safety of their products. Palisade Bio, Inc. (PALI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

J. D. Finley

Employees

14

Headquarters

Denver

Upcoming events

09 NOV

Earnings

Upcoming earnings report

50d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.